Omega-3 fatty acid supplementation improves endothelial function in primary antiphospholipid syndrome: a small-scale randomized double-blind placebo-controlled trial
Autor: | Sheylla M Felau, Maria Claudia Irigoyen, Fernanda Marciano Consolim-Colombo, Hamilton Roschel, Ana Paula Hayashi, Lucas Peixoto Sales, Eloisa Bonfa, Keyla Y. Katayama, Danieli Andrade, Marina Yazigi Solis, Ana Lúcia de Sá-Pinto, Fabiana Braga Benatti, Bruno Gualano |
---|---|
Rok vydání: | 2018 |
Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine Adult medicine.medical_specialty Immunology Placebo-controlled study 030204 cardiovascular system & hematology Placebo Gastroenterology law.invention n-3 PUFA 03 medical and health sciences 0302 clinical medicine Randomized controlled trial endothelial function Double-Blind Method Antiphospholipid syndrome law Internal medicine Fatty Acids Omega-3 Immunology and Allergy Medicine Humans coagulation Adverse effect Reactive hyperemia chemistry.chemical_classification business.industry MÉTODO DUPLO-CEGO Blood Proteins Middle Aged medicine.disease Antiphospholipid Syndrome Clinical Trial Endothelial stem cell 030104 developmental biology chemistry inflammation Dietary Supplements Female Endothelium Vascular lcsh:RC581-607 business Biomarkers Polyunsaturated fatty acid |
Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Frontiers in Immunology Frontiers in Immunology, Vol 9 (2018) |
Popis: | Endothelial cells are thought to play a central role in the pathogenesis of antiphospholipid syndrome (APS). Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation has been shown to improve endothelial function in a number of diseases; thus, it could be of high clinical relevance in APS. The aim of this study was to evaluate the efficacy of n-3 PUFA supplementation on endothelial function (primary outcome) of patients with primary APS (PAPS). A 16-week randomized clinical trial was conducted with 22 adult women with PAPS. Patients were randomly assigned (1:1) to receive placebo (PL, n = 11) or n-3 PUFA (ω-3, n = 11) supplementation. Before (pre) and after (post) 16 weeks of the intervention, patients were assessed for endothelial function (peripheral artery tonometry) (primary outcome). Patients were also assessed for systemic markers of endothelial cell activation, inflammatory markers, dietary intake, international normalized ratio (INR), and adverse effects. At post, ω-3 group presented significant increases in endothelial function estimates reactive hyperemia index (RHI) and logarithmic transformation of RHI (LnRHI) when compared with PL (+13 vs. −12%, p = 0.06, ES = 0.9; and +23 vs. −22%, p = 0.02, ES = 1.0). No changes were observed for e-selectin, vascular adhesion molecule-1, and fibrinogen levels (p > 0.05). In addition, ω-3 group showed decreased circulating levels of interleukin-10 (−4 vs. +45%, p = 0.04, ES = −0.9) and tumor necrosis factor (−13 vs. +0.3%, p = 0.04, ES = −0.95) and a tendency toward a lower intercellular adhesion molecule-1 response (+3 vs. +48%, p = 0.1, ES = −0.7) at post when compared with PL. No changes in dietary intake, INR, or self-reported adverse effects were observed. In conclusion, 16 weeks of n-3 PUFA supplementation improved endothelial function in patients with well-controlled PAPS. These results support a role of n-3 PUFA supplementation as an adjuvant therapy in APS. Registered at http://ClinicalTrials.gov as NCT01956188. |
Databáze: | OpenAIRE |
Externí odkaz: |